The safety and efficacy of monoclonal antibody therapy with low-dose bamlanivimab plus etesevimab was similar to that of higher doses of the drug combination in patients with mild to moderate ...
Also, would a combination of these drugs result in greater symptomatic relief and an improvement in peak urinary flow (Q max)? The first question has largely been answered by a 4-year trial with ...